Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrinsa for HSDD in surgically menopausal women on estrogen therapy
NCT00331123Phase 3Completed
- Sponsor
- Warner Chilcott
- Start
- May 2002
- Primary completion
- Dec 2003
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of Testosterone TEPI patch in hypoactive sexual desire disorder (HSDD) (2 arms), sponsored by Warner Chilcott. Primary endpoint: Frequency of total satisfying sexual activity at 24 weeks. Started May 2002; status: completed.
02
Drugs
Testosterone TEPI patch
03
Conditions
hypoactive sexual desire disorder (HSDD)
Beyond the preview
Go deeper on NCT00331123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331123.